A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2014
At a glance
- Drugs Iniparib (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- 21 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Sep 2013 Planned end date changed from 1 Aug 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.